$13.1 Million Backs Bacterial Therapies
2026-10-09
An unlikely weapon advances. A $13.1 million grant backs complementary research involving a scientist at Weill Cornell Medicine and colleagues at the University of Massachusetts Amherst, who are engineering therapeutic Salmonella to address treatment gaps in drug-resistant triple-negative breast cancer. The wager is biological. Bacteria associated with illness are being investigated as instruments against a disease that can resist existing medicines.
Resistance changes the calculation. Triple-negative breast cancers lack estrogen receptors, progesterone receptors and excess human epidermal growth factor receptor 2, or HER2, which means treatments directed at those targets generally cannot provide the same options available for other breast cancer subtypes. Options still exist. Chemotherapy and, for some patients, immunotherapy or other targeted medicines remain available, but drug resistance can narrow their usefulness, making approaches that operate differently worth investigating. Difference is not proof. The funded collaboration concerns engineered bacterial therapies, not evidence that Salmonella has already solved resistance or produced a treatment ready for routine patient care.
Control matters more than novelty. The appeal of therapeutic bacteria depends on whether researchers can harness their biological activity against tumors while limiting harm, a demanding distinction when the proposed treatment begins with an organism known for causing infection. Funding buys investigation time. The award supports complementary efforts at the two institutions, but the supplied announcement does not establish patient outcomes, clinical availability or the precise engineering methods each team will use. The tension remains unresolved. A bacterium must cease to be merely an intruder before it can become medicine.
Loading...
